Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | HRH2 | P25021 | 4/20 | 0.43 |
| ▸ | HRH1 | P35367 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15163479 | 0.88 | HRH3 (0.44) | HRH3HRH2HRH1KCNH2KDM1A | |
| SCHEMBL6094143 | 0.87 | HRH3 (0.57) | HRH3HRH2HRH1KDM1ASSTR4 | |
| Hydrochloric Acid SCHEMBL3122612 | 0.87 | HRH3 (0.43) | HRH3HRH2HRH1KCNH2KDM1A | |
| Hydrochloric Acid SCHEMBL1618281 | 0.87 | HRH3 (0.43) | HRH3HRH2HRH1KCNH2KDM1A | |
| SCHEMBL2963282 | 0.84 | KCNH2 (0.37) | HRH3HRH2HRH1KCNH2KDM4E | |
| SCHEMBL1619310 | 0.83 | HRH3 (0.60) | HRH3HRH2HRH1KCNH2 | |
| SCHEMBL4418109 | 0.83 | KDM4E (0.41) | KCNH2KDM4EALDH1A1 | |
| SCHEMBL4133154 | 0.82 | KCNH2 (0.43) | KCNH2KDM4EALDH1A1SSTR4 | |
| SCHEMBL1619397 | 0.82 | HRH3 (0.50) | HRH3HRH2HRH1KCNH2KDM1A | |
| SCHEMBL2956486 | 0.81 | KCNH2 (0.43) | HRH3HRH2HRH1KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772229-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, (SE) | 2009-12-31 | — | — | US | disclosed |
| US-7351821-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB, SODERTALJE, SWEDEN | 2007-05-24 | — | — | US | disclosed |
| US-7164017-B2 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | disclosed |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1559717-A2 | Oxabispidine compounds useful in the treatment of cardiac arrythmias | AstraZeneca AB (SE) | 2005-08-03 | — | — | EP | disclosed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB | 2003-08-14 | — | — | US | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153564-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, RYR1 | HRH3 936/4885HRH2 680/4885HRH1 765/4885 |
| US-20090326221-A1 | New oxabispidine compunds useful in the treatment of cardiac arrhythmias | KCNH1, CACNA1E, SCN1B | HRH3 817/4885HRH2 1257/4885HRH1 970/4885 |
| US-20060166979-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 385/4885HRH2 505/4885HRH1 526/4885 |
| US-20070117799-A1 | Oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 420/4885HRH2 556/4885HRH1 591/4885 |
| US-20060166980-A1 | New oxabispidine compounds useful in the treatment of cardiac arrhythmias | KCNH1, RYR1, CACNA1E | HRH3 385/4885HRH2 505/4885HRH1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.